Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) will release its full year 2025 financial results after market close on April 15, 2026 and hold a conference call the same day at 5:00 pm ET.
Management will review results, discuss strategic collaborations, and provide operational updates. A live webcast and a replay (passcode 1153783) will be available; the replay is accessible until April 29, 2026 and the webcast archive for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – VVOS
In the Apr 15 session, VVOS gained 8.89%, reflecting a notable positive market reaction. Argus tracked a peak move of +21.1% during that session. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.8x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Q3 2025 results call | Neutral | -4.5% | Scheduled Q3 2025 results release and conference call with operational updates. |
| Aug 19 | Q2 2025 results call | Neutral | -4.0% | Announced Q2 2025 results timing and investor conference call details. |
| May 14 | Q1 2025 results call | Neutral | -3.2% | Set date and access details for Q1 2025 financial results call. |
| Mar 28 | FY 2024 results call | Neutral | -2.5% | Scheduled full-year 2024 results release and conference call for investors. |
| Nov 13 | Q3 2024 results call | Neutral | +0.0% | Announced Q3 2024 results release date and related investor call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings/call announcements have typically seen modest negative next-day moves around results timing.
Over the last six months, VVOS combined capital raises and strategic execution with recurring earnings call scheduling. Financings in January–April 2026 (warrants, PIPE, and a convertible note) focused on working capital and growth. Operational updates highlighted insurer network expansion, cost reductions, and clinical validation for its OSA-focused devices. Within this backdrop, the current full-year 2025 results call fits an ongoing cadence of quarterly and annual updates that frame progress on collaborations, revenue growth, and cash burn.
Key Terms
obstructive sleep apnea medical
osa medical
cash burn financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Call scheduled for today, Wednesday, April 15, 2026, at 5:00 pm ET
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates.
Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic collaborations and their anticipated effect on near-term revenue growth and cash burn.
To access Vivos’ investor conference call, please dial (800) 717-1738 or (646) 307-1865 for international callers. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921 or (412) 317-6671 for international callers. The passcode for the replay is 1153783. The replay will be available until April 29, 2026.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investors/. An online archive of the webcast will be available on Vivos’ website for 30 days following the call.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and conference call referred to herein, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” “is expected to,” and variations of such words and similar expressions are intended to identify forward-looking statements.
In this press release, forward-looking statements include, without limitation, those relating to the Company's goal of becoming cash flow positive.
These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future revenues and results of operations and the anticipated benefits of the Company’s new marketing and distribution model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (v) market and other conditions, and (vi) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
